Genomics and anti-CD20 depleting antibodies

There are lots of different B cell depleting antibodies used in cancer and autoimmunity. There are three approved for MS (in blue below. Ublituximab, ocrelizumab and ofatumumab), but rituximab is used a lot in some countries. The target binding bit of the antibodies give the specificity but the fragment crystallizable mediate the effector function of [ ]